We are live on ! Find out more
ANIX icon

Anixa Biosciences

58 hedge funds and large institutions have $16M invested in Anixa Biosciences in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more call options, than puts

Call options by funds: $122K | Put options by funds: $71K

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

18% more capital invested

Capital invested by funds: $13.6M → $16M (+$2.48M)

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

2% more funds holding

Funds holding: 5758 (+1)

0.74% less ownership

Funds ownership: 18.15%17.41% (-0.74%)

Holders
58
Holders Change
+1
Holders Change %
+1.75%
% of All Funds
0.78%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
11
Reduced
7
Closed
7
Calls
$122K
Puts
$71K
Net Calls
+$51K
Net Calls Change
-$88K

ANIX Hedge Fund Activity: Q1 2025 in Review

58 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2025, worth a combined $16M — up 18% from $13.6M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ANIX positions and 7 closed out — a net gain of 1 holder — while 11 added to existing stakes and 7 trimmed.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $217K. The largest seller was Long Focus Capital Management, exiting entirely with an estimated $342K sold.

  • 58 institutional investors held Anixa Biosciences (ANIX) as of Q1 2025, up from 57 in Q4 2024.
  • Funds reported $16M of Anixa Biosciences stock for Q1 2025, up 18% quarter-over-quarter.
  • 8 funds opened new Anixa Biosciences positions in Q1 2025 and 7 closed out, a net change of +1 holder.
  • The largest Anixa Biosciences buyer in Q1 2025 was GSA Capital Partners, an estimated $217K added.
  • The largest Anixa Biosciences seller in Q1 2025 was Long Focus Capital Management, an estimated $342K sold.

Based on aggregated 13F filings for Q1 2025.